Figure 2. Graphic representation of patients with hypothesized response to EGFR-targeted therapy.

Percent-wise distribution of aberrations for KRAS, BRAF, PIK3CA and PTEN and their combinations, in the <50 age group and >70 age group. Patients negative for all mutations (quadruple negative) are potential responders to anti-EGFR-therapy. (Modified from Bardelli et al. [29])